IMAP advises pharma quality control company Lixis on cross-border sale to SEA Vision
IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.
IMAP is pleased to announce the sale of pharmaceutical quality control company Lixis, to SEA Vision, a global leader in pharmaceutical inspection systems. Terms of the transaction were not disclosed.
SEA Vision is an Italian company specializing in vision and track-and-trace systems for the pharmaceutical industry. Lixis is an Argentinian company with over 17 years of experience in pharmaceutical vision, control and track-and-trace systems.
The operational synergies between the companies will enable SEA Vision to become the leading group providing both software and hardware in its target market in Latin America, with a local workforce of 70 professionals. Lixis has already been collaborating with SEA Vision in the Brazilian market through the São Paulo-based subsidiary SEA Vision Latin America (SVLA).
IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.